Synthetic Biology in Cancer Immunotherapy: Engineering Bacteria to Inhibit IDO Activity and Reprogram CD8+ T Cell Responses Academic Background In recent years, significant progress has been made in cancer immunotherapy, particularly through the activation of T cells to combat tumors. However, metabolic adaptations in the tumor microenvironment (TM...
Study on the Association Between Long-Term Cancer Risk and Epigenetic Age in Stroke Survivors Background and Significance Cancer and stroke are leading global causes of morbidity and mortality, with their association being increasingly recognized. Statistics show that about 6% of cancer patients experience a stroke during their lifetime, while stro...
Neoadjuvant Oncolytic Virus OrienX010 Combined with PD-1 Inhibitor Toripalimab for Resectable Acral Melanoma: Phase Ib Clinical Trial Background Acral melanoma (AM) is a highly aggressive subtype of melanoma with a high incidence in the Chinese population, accounting for approximately 40% of melanoma cases. Despite advances in melanoma treatment, c...
Research Report on Efferocytosis Features and Their Prognostic and Immunotherapy Associations in Lung Adenocarcinoma Background and Research Motivation Lung cancer is a leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) being the most common histological subtype. Due to the insidious nature of the disease and lack ...
Tumor Analysis of BRCA1/2 Carriers: Genomic Similarities Evident Across Different Time Points Breast cancer (BC) is the most common malignant tumor among women globally, with its pathogenesis predominantly sporadic, while familial hereditary cases account for only 5% to 10%. Among various pathogenic molecules, mutations in the BRCA1/2 genes (Pathog...
The Impact of Radioresistant-Related Telomere Genes on Prognosis and Immune Infiltration in Lung Adenocarcinoma Lung adenocarcinoma (LUAD), a common subtype of non-small cell lung cancer (NSCLC), has a high incidence and mortality rate. Despite significant progress in early detection and treatment, the overall survival (OS) rate of LUAD patients re...